"This laboratory report provides timely evidence that BIOGUARD dressings can have a role to play, not only as an antibacterial in infection prevention programs, but also as a tool to help decrease the spread of the H1N1 virus," said Edward J. Quilty, Chairman and CEO of Derma Sciences. "These patented dressings harness the antimicrobial properties of a unique biocide known as Poly(DADMAC), which is inherently bactericidal and has been shown to be nontoxic in the standard battery of required biocompatibility tests."

Quilty added that use of BIOGUARD dressings involve virtually no chance of developing resistant bacterial strains, making the dressing ideal for widespread prophylactic usage. "From a global perspective, our objective is to develop BIOGUARD(TM) as the cost-effective dressing that clinicians utilize for infection prevention. Its patented design makes it an ideal dressing for this use."

SOURCE Derma Sciences, Inc.